The Food and Drug Administration on Saturday authorized Johnson & Johnson’s single-dose adenovirus vector COVID-19 vaccine for adults aged 18 and older following Friday’s unanimous endorsement by the agency’s panel of outside experts.
In J&J’s 44,000-person global trial, the vaccine was found to be 66 percent effective at preventing moderate-to-severe COVID-19 four weeks after inoculation, and 100 percent effective in preventing hospitalization and death due to the virus.
